Indolobenzazepine HCV NS5B inhibitors
US7473688B2 · kind B2 · utility
17Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2006 |
| Grant date | Jan 6, 2009 |
| Priority date | — |
| Expiry date | Dec 28, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.